HOLLISTON, Mass., Feb. 23, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2016 after market trading hours on Thursday, March 9, 2017. A conference call to discuss the company's fourth quarter 2016 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 44422279.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through March 16, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


CATL Stock Hits Record High After Q1 2025 Earnings Surge
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 



